Related Experiment Video
Updated: Aug 15, 2026

Three Dimensional Cultures: A Tool To Study Normal Acinar Architecture vs. Malignant Transformation Of Breast Cells
Published on: April 25, 2014
Abnormal expression of MDM-2 in breast carcinomas
C E Bueso-Ramos1, T Manshouri, M A Haidar
1Department of Laboratory Medicine, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Abstract:
MDM-2 is a cellular oncoprotein that binds to the p53 protein and abrogates its growth-suppressing function. At least seven MDM-2 mRNAs and five proteins (p90, p85, p76, p74, and p57) have been reported in tissue culture. MDM-2 gene amplification occurs in human sarcomas and high-grade gliomas. MDM-2 overexpression without gene amplification has been reported in leukemias and lymphomas. Here we report MDM-2 mRNA overexpression in 24 (73%) out of 33 cases of human breast carcinoma as compared with normal breast tissue. The MDM-2 overexpression was seen in the absence of MDM-2 gene amplification. MDM-2 protein expression was studied by western blot analysis in 21 of these cases of carcinoma. We found complete concordance between MDM-2 mRNA overexpression and MDM-2 protein levels. MDM-2 proteins were overexpressed in 15 of 21 breast carcinoma tissue samples but not in normal breast tissue controls. Ten of these fifteen cases overexpressed MDM-2 p57 protein, two cases overexpressed both p57 and p90, and three cases overexpressed only p90. MDM-2 overexpression was confirmed by immunohistochemistry. p53 overexpression was also studied by immunohistochemistry, 69% of breast carcinomas that overexpressed the MDM-2 mRNA had detectable nuclear p53 protein. These findings demonstrate that MDM-2 oncoprotein expression is altered in primary human breast carcinomas at both mRNA and protein levels. In addition, our results suggest that MDM-2 p57 protein represents the main MDM-2 protein altered in breast carcinomas.
Insights
MDM-2 oncoprotein is overexpressed in most breast cancers, affecting p53 function. This study found MDM-2 mRNA and protein alterations, particularly the p57 variant, in human breast carcinoma tissues.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- MDM-2 is a cellular oncoprotein that inhibits the tumor suppressor p53.
- MDM-2 alterations, including gene amplification and overexpression, are implicated in various cancers.
- Specific MDM-2 protein isoforms like p57 are known to exist.
Purpose of the Study:
- To investigate MDM-2 mRNA and protein expression in human breast carcinoma.
- To determine if MDM-2 overexpression occurs independently of gene amplification in breast cancer.
- To identify the predominant MDM-2 protein isoforms involved in breast carcinoma.
Main Methods:
- Quantitative analysis of MDM-2 mRNA levels in breast carcinoma and normal tissues.
- Western blot analysis to assess MDM-2 protein expression and isoforms.
- Immunohistochemistry to confirm MDM-2 and p53 protein expression.
- Analysis of MDM-2 gene amplification status.
Main Results:
- MDM-2 mRNA overexpression was observed in 73% of breast carcinomas, without gene amplification.
- A strong correlation was found between MDM-2 mRNA and protein overexpression.
- MDM-2 protein overexpression, particularly the p57 isoform, was detected in 15 out of 21 breast carcinoma samples.
Conclusions:
- MDM-2 oncoprotein expression is significantly altered at both mRNA and protein levels in primary human breast carcinomas.
- MDM-2 overexpression in breast cancer occurs independently of gene amplification.
- The MDM-2 p57 protein isoform appears to be the primary altered form in breast carcinomas, suggesting its potential role in tumorigenesis.
Related Concept Videos
Epigenetic Regulation
Master Transcription Regulators
Mitogens and the Cell Cycle
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...

